Medication info
Nexprazole 20mg (Esomeprazole Magnesium Trihydrate)

Nexprazole 20mg (Esomeprazole Magnesium Trihydrate)

Prescription medicationTabletOral · Intravenous injection
Ingredient · strength
Esomeprazole Magnesium Dihydrate›21.69mg / 1 tablet
Manufacturer / importer
Hanwha Pharmaceutical Co., Ltd.
Appearance
Pink round film-coated tablets
Packaging
28 tablets (14 tablets / Alu-Alu X 2)
Approval status
Active

MFDS item code 201600986 · Approved 2016.02.22 · Insurance code 651601970

Summary

Main use
Treatment of acid-related disorders (reflux, Zollinger-Ellison syndrome), Helicobacter pylori infection and ulcers, and gastrointestinal symptoms caused by anti-inflammatory analgesics
Who uses it
Adults · Children
Adult dosage
1. Adults 1) Gastroesophageal reflux disease (GERD). - Treatment of erosive reflux esophagitis: Administer 40 mg once daily for 4 weeks. For patients whose esophagitis has not healed or whose symptoms persist, continue treatment for an additional 4 weeks. - Long-term maintenance therapy to prevent recurrence in patients with esophagitis: 20 mg once daily - Symptomatic treatment of gastroesophageal reflux disease without esophagitis: · 20 mg once daily. If symptoms are not controlled after 4 weeks, further evaluation is required. · Once symptoms have resolved, control subsequent recurring symptoms by administering 20 mg once daily. · In adults, 20 mg may be administered once daily as needed. In patients at high risk of developing gastric or duodenal ulcers due to administration of nonsteroidal anti-inflammatory drugs, as-needed administration is not recommended for controlling recurring symptoms. 2) Combination therapy with antibiotics for eradication of Helicobacter pylori Administer 20 mg of this medicine in combination with 1 g of amoxicillin and 500 mg of clarithromycin twice daily for 7 days. 3) Short-term treatment of upper gastrointestinal symptoms (pain, discomfort, burning sensation) associated with administration of nonsteroidal anti-inflammatory drugs (nonselective or selective COX-2 inhibitors) - 20 mg once daily. If symptoms are not controlled after 4 weeks, further evaluation is required. Clinical trials lasting more than 4 weeks have not been conducted. 4) Patients requiring continued administration of nonsteroidal anti-inflammatory drugs - Treatment of gastric ulcers associated with administration of nonsteroidal anti-inflammatory drugs: 20 mg once daily. The treatment period is 4∼8 weeks. - Prevention of gastric and duodenal ulcers associated with administration of nonsteroidal anti-inflammatory drugs: 20 mg once daily. 5) Treatment of Zollinger-Ellison syndrome The recommended initial dose is 40 mg twice daily. The dose should then be adjusted individually for each patient, and treatment should continue while clinical symptoms are present. Clinical data indicate that most patients can be controlled with doses of 80 ∼ 160 mg per day. Doses above 80 mg per day should be divided into 2 doses. 6) Maintenance therapy following intravenous treatment to induce prevention of rebleeding due to gastric or duodenal ulcers Administer 40 mg once daily for 4 weeks following intravenous treatment to induce prevention of rebleeding due to gastric or duodenal ulcers. 4. Renal impairment No dose adjustment is necessary. Use with caution because there is limited experience in patients with severe renal impairment. 5. Hepatic impairment No dose adjustment is necessary in patients with mild to moderate hepatic impairment. In patients with severe hepatic impairment, do not exceed 20 mg of this medicine. 6. Elderly patients No dose adjustment is necessary.
Children's dosage
Adolescents aged 12 years and older: Treatment of erosive reflux esophagitis: Administer 40 mg once daily for 4 weeks. For patients whose esophagitis has not healed or whose symptoms persist, continue treatment for an additional 4 weeks. Adolescents aged 12 years and older: Symptomatic treatment of gastroesophageal reflux disease without esophagitis: 20 mg once daily. If symptoms are not controlled after 4 weeks, further evaluation is required. Adolescents aged 12 years and older: Once symptoms have resolved, control subsequent recurring symptoms by administering 20 mg once daily. Children under 12 years: There is no experience with administering this medicine to children under 12 years of age.

Ingredients

Manufacturer
Hanwha Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of acid-related disorders (reflux, Zollinger-Ellison syndrome), Helicobacter pylori infection and ulcers, and gastrointestinal symptoms caused by anti-inflammatory analgesics

  • Gastroesophageal reflux disease
  • erosive esophagitis
  • esophagitis
  • symptoms of gastroesophageal reflux disease without esophagitis
  • Helicobacter pylori-positive duodenal ulcers
  • peptic ulcers
  • upper gastrointestinal symptoms
  • pain
  • discomfort
  • burning sensation
  • gastric ulcer related to non-steroidal anti-inflammatory drug administration
  • duodenal ulcers
View approved original text

This medication is used for the treatment of gastroesophageal reflux disease and erosive esophagitis, and it is effective as a long-term maintenance therapy to prevent recurrence in patients with esophagitis. It also helps alleviate symptoms of gastroesophageal reflux disease in absence of esophagitis. This drug is utilized for the treatment and prevention of recurrence of duodenal ulcers and peptic ulcers caused by Helicobacter pylori infection. It is effective for the treatment, prevention of gastric ulcers and duodenal ulcers related to the use of non-steroidal anti-inflammatory drugs, and is also used for the treatment of Zollinger-Ellison syndrome. It assists in the maintenance therapy to prevent rebleeding from gastric or duodenal ulcers post intravenous injection. This medication is beneficial for the treatment and prevention of various gastrointestinal diseases.

Dosage and Administration

Adult dosage

1. Adults 1) Gastroesophageal reflux disease (GERD). - Treatment of erosive reflux esophagitis: Administer 40 mg once daily for 4 weeks. For patients whose esophagitis has not healed or whose symptoms persist, continue treatment for an additional 4 weeks. - Long-term maintenance therapy to prevent recurrence in patients with esophagitis: 20 mg once daily - Symptomatic treatment of gastroesophageal reflux disease without esophagitis: · 20 mg once daily. If symptoms are not controlled after 4 weeks, further evaluation is required. · Once symptoms have resolved, control subsequent recurring symptoms by administering 20 mg once daily. · In adults, 20 mg may be administered once daily as needed. In patients at high risk of developing gastric or duodenal ulcers due to administration of nonsteroidal anti-inflammatory drugs, as-needed administration is not recommended for controlling recurring symptoms. 2) Combination therapy with antibiotics for eradication of Helicobacter pylori Administer 20 mg of this medicine in combination with 1 g of amoxicillin and 500 mg of clarithromycin twice daily for 7 days. 3) Short-term treatment of upper gastrointestinal symptoms (pain, discomfort, burning sensation) associated with administration of nonsteroidal anti-inflammatory drugs (nonselective or selective COX-2 inhibitors) - 20 mg once daily. If symptoms are not controlled after 4 weeks, further evaluation is required. Clinical trials lasting more than 4 weeks have not been conducted. 4) Patients requiring continued administration of nonsteroidal anti-inflammatory drugs - Treatment of gastric ulcers associated with administration of nonsteroidal anti-inflammatory drugs: 20 mg once daily. The treatment period is 4∼8 weeks. - Prevention of gastric and duodenal ulcers associated with administration of nonsteroidal anti-inflammatory drugs: 20 mg once daily. 5) Treatment of Zollinger-Ellison syndrome The recommended initial dose is 40 mg twice daily. The dose should then be adjusted individually for each patient, and treatment should continue while clinical symptoms are present. Clinical data indicate that most patients can be controlled with doses of 80 ∼ 160 mg per day. Doses above 80 mg per day should be divided into 2 doses. 6) Maintenance therapy following intravenous treatment to induce prevention of rebleeding due to gastric or duodenal ulcers Administer 40 mg once daily for 4 weeks following intravenous treatment to induce prevention of rebleeding due to gastric or duodenal ulcers. 4. Renal impairment No dose adjustment is necessary. Use with caution because there is limited experience in patients with severe renal impairment. 5. Hepatic impairment No dose adjustment is necessary in patients with mild to moderate hepatic impairment. In patients with severe hepatic impairment, do not exceed 20 mg of this medicine. 6. Elderly patients No dose adjustment is necessary.

Children's dosage

Adolescents aged 12 years and older: Treatment of erosive reflux esophagitis: Administer 40 mg once daily for 4 weeks. For patients whose esophagitis has not healed or whose symptoms persist, continue treatment for an additional 4 weeks. Adolescents aged 12 years and older: Symptomatic treatment of gastroesophageal reflux disease without esophagitis: 20 mg once daily. If symptoms are not controlled after 4 weeks, further evaluation is required. Adolescents aged 12 years and older: Once symptoms have resolved, control subsequent recurring symptoms by administering 20 mg once daily. Children under 12 years: There is no experience with administering this medicine to children under 12 years of age.

Precautions

This medication should not be administered to certain patients. Patients who have allergy or hypersensitivity to this drug or its components, or to benzimidazole derivatives, should not use it. Moreover, patients with hypersensitivity to antibiotics amoxicillin or clarithromycin should not be administered when used in combination for the eradication of Helicobacter pylori. Patients taking specific heart medications or with a history of myocardial infarction, as well as nursing women, should not use this medication. This medication may cause various side effects. Gastrointestinal symptoms such as headache, abdominal pain, diarrhea, nausea, and vomiting may occur frequently, and sometimes neurological symptoms like dizziness and insomnia are also reported. Rarely, serious side effects such as decreased blood cell count, hypersensitivity reactions, liver function anomalies, skin rashes, and myalgia may occur, requiring immediate consultation with a physician if symptoms are severe or persistent. With long-term use, electrolyte disturbances such as hypomagnesemia may arise, necessitating regular testing. This medication inhibits gastric acid secretion, thereby lowering gastric acidity, which can alter the normal bacterial balance in the gastrointestinal tract, potentially increasing the risk of certain infections. Additionally, long-term or high-dose usage may elevate the risk of fractures, so caution is advised in patients with a risk of osteoporosis. This medication has a high potential for interaction with other drugs. Particularly, when used in combination with antibiotics, antivirals, anticoagulants, antidepressants, etc., the effects of the drugs may change, making it imperative to inform your doctor or pharmacist about medications currently being taken. Moreover, co-administration with certain drugs may alter the plasma concentration of this medication or other medications, necessitating caution. Due to limited data on safety during pregnancy, pregnant women should use this medication cautiously and after consulting a physician. Nursing women should avoid this medication since it may be excreted in breast milk. There are no specific antidotes for overdose, so symptomatic treatment and general management are necessary; it should be stored out of reach of children to ensure safety. Additionally, transferring to another container is advised against due to the risk of quality degradation or misuse.

Side effects

Leukopenia, thrombocytopenia, agranulocytosis, pancytopenia, fever, angioedema, anaphylactic reaction, shock, peripheral edema, hyponatremia, hypomagnesemia, insomnia, anxiety, mental confusion, depression, aggression, hallucinations, headache, dizziness, paresthesia, drowsiness, taste disorder, blurred vision, bronchospasm, pancreatitis, abdominal pain, constipation, diarrhea, abdominal distension, nausea, vomiting, dry mouth, stomatitis, gastrointestinal candidiasis, microscopic colitis, elevated liver enzymes, jaundice, hepatitis, liver failure, encephalopathy, dermatitis, itching, rash, urticaria, hair loss, photosensitivity, erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis, acute generalized exanthematous pustulosis, eosinophilia, drug reaction with systemic symptoms, fracture, arthralgia, myalgia, muscle weakness, interstitial nephritis, gynecomastia, asthenia, increased sweating, Clostridium difficile-associated diarrhea, abdominal distension, allergic reaction, back pain, chest pain, retrosternal pain, facial edema, facial flushing, fatigue, fever, influenza-like illness, generalized edema, leg edema, malaise, pain, stiffness, peripheral edema, flushing, hypertension, tachycardia, thyroid goiter, irritable bowel syndrome, worsened constipation, dyspepsia, dysphagia, gastrointestinal developmental disorder, upper abdominal pain, belching, esophageal disorder, frequent bowel movements, gastritis, gastrointestinal bleeding, hiccups, melena, oral disorders, pharyngeal disorders, rectal disorders, gastrointestinal symptoms, increased serum gastrin, tongue disorders, tongue edema, ulcerative stomatitis, vomiting, earache, tinnitus, anemia, hypochromic anemia, cervical lymphadenopathy, epistaxis, leukocytosis, leukopenia, thrombocytopenia, hyperbilirubinemia, liver dysfunction, increased ALT, increased AST, diabetes, hyperuricemia, increased ALP, polydipsia, vitamin B12 deficiency, weight gain, weight loss, exacerbation of arthritis, arthropathy, seizures, fibromyalgia syndrome, hernia, polymyalgia rheumatica, arthralgia, anorexia, apathy, increased appetite, confusion, exacerbation of depression, muscle hypertonicity, anxiety, sensory decrease, erectile dysfunction, insomnia, migraine, exacerbation of migraine, sleep disorders, tremors, dizziness, visual field loss, paresthesia, drowsiness, dysmenorrhea, menstrual disorders, vaginitis, exacerbation of asthma, cough, dyspnea, laryngeal edema, pharyngitis, rhinitis, sinusitis, acne, anal itching, rash, erythematous rash, papular rash, angioedema, dermatitis, itching, urticaria, increased sweating, otitis media, dysosmia, taste loss, taste dysfunction, abnormal urination, albuminuria, cystitis, dysuria, fungal infection, hematuria, urination frequency, candidiasis, genital candidiasis, polyuria, conjunctivitis, visual disturbances, duodenitis, esophagitis, esophageal stricture, esophageal ulcer, esophageal varices, gastric ulcer, gastritis, benign polyp, nodule, Barrett's esophagus, mucosal discoloration, hernia, systemic lupus erythematosus, cutaneous lupus erythematosus, glandular polyps, hypocalcemia, hypokalemia, rhabdomyolysis

Not everyone experiences these, and they can vary from person to person.

Storage

This medication may be sensitive to air and moisture, so it should be stored in a tightly sealed container. It is advisable to maintain a storage temperature between 1 and 30 degrees Celsius. Proper storage will safeguard the medication's efficacy.

Appearance and packaging

Appearance

Pink round film-coated tablets

Package unit

28 tablets (14 tablets / Alu-Alu X 2)

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.